aflibercept-ayyh (Pavblu) vs HLX04-O
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
aflibercept-ayyh (Pavblu)
Marketed by Amgen
NCT04270747 · Phase 3 · completed
This was a randomized, double-masked, active-controlled trial with 576 participants, comparing ABP 938 with aflibercept. The clinical primary endpoint was met for similarity: the 90% confidence interval for the treatment difference in Week 8 visual-acuity change (-1.1 to 1.3 ETDRS letters) was entirely within the prespecified -3 to 3 letter margin.
Reported efficacy
Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) (met)
Result source: NCT04270747
HLX04-O
Developed by Essex Bio-Technology Limited under a licence from Shanghai Henlius Biotech
NCT04740671 · Phase 3 · completed
This randomized, double-blind Phase 3 trial assigned 410 people with wet age-related macular degeneration to intravitreal HLX04-O or the active comparator ranibizumab, with mean change in best-corrected visual acuity at Week 36 as its non-inferiority primary endpoint. Registry results are not posted; the sponsor reports that the primary and key secondary (Week 48) endpoints were met, with HLX04-O non-inferior to ranibizumab, without giving figures, so the size of the effect cannot be checked.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
No aligned efficacy figure on record for this race.
Results for Age-Related Macular Degeneration
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
HLX04-O: no structured comparison results are available for Age-Related Macular Degeneration.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
aflibercept-ayyh (Pavblu)
show 8 more results
show 3 more results
show 7 more results
Available safety results
aflibercept-ayyh (Pavblu)
| Dropout rate | 5.2%ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results—Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 —Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
|---|---|
| Discontinued due to AEs | 0.3%ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results—Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 —Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Serious AEs | —ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results8.1%Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.1%Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Most frequent reported AEs | neovascular age-related macular degeneration 5.9% conjunctival haemorrhage 1.5% NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 1 more resultconjunctival haemorrhage 4.2% neovascular age-related macular degeneration 2.1% NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aflibercept-ayyh (Pavblu)'s landscape · HLX04-O's landscape